



---

**CONTROLLED FOREIGN CORPORATION INFORMATION STATEMENT  
CLEMENTIA PHARMACEUTICALS INC.**

---

This Information Statement is for the taxable year of Clementia Pharmaceuticals Inc. (the **Corporation**) beginning on January 1, 2017 and ending on December 31, 2017 (the **Taxable Year**) and is issued to the Corporation's Investors and their Partners.

For the Taxable Year, the Corporation:

was a controlled foreign corporation ("CFC").

was not a CFC.

**Subpart F Income**

Taxable transactions under IRC 951(a) include Subpart F Income (IRC section 952). Subpart F Income includes foreign based company income (IRC section 954) consisting, for the Corporation, of passive investment income in the total amount of \$1,082,030 for the Taxable Year. However, before considering the includible amounts, the following exclusion should be considered.

**Limitations as to Earnings and Profits**

Subpart F Income includible in gross income by a U.S. shareholder for any taxable year may not exceed the CFC's earnings and profits for the taxable year (IRC section 952(c)(1)(A)). As the Corporation realized a net and comprehensive loss of approximately \$116,216,340 on a non-consolidated basis for the Taxation Year, the amount of Subpart F Income includible in gross income by a U.S. shareholder is determined to be \$nil for the Taxation Year.

The Corporation will permit investors and their direct or indirect owners to inspect and copy the Corporation's permanent book of account, records and other such Corporation documents as necessary to establish that Subpart F Income includable in gross income by a U.S. shareholder is reported according to U.S. standards.

Date: February 27, 2018

CLEMENTIA PHARMACEUTICALS INC.

By:                     /s/ Michael Singer                      
Michael Singer, Chief Financial Officer